BrainStorm Cell’s (BCT) NurOwn enables extracted mesenchymal stem cells (MSCs) to express neurotrophic factors that can support cells affected by neurodegenerative diseases. Early work in amyotrophic lateral sclerosis (ALS) has shown signs of slowing down the rate of disease progression which, if replicated in the current US Phase II study, should lead to a marked re-rating given significant unmet medical need. Our rNPV valuation is $98m.
